The primary aim of this trial is to assess the efficacy of resuscitative endovascular balloon occlusion of the aorta (REBOA) as an adjunct treatment to advanced cardiovascular life support (ACLS) in patients with out-of-hospital cardiac arrest. Out of hospital cardiac arrest (OHCA) carries a high mortality rate. The treatment of out-of-hospital cardiac arrest is ACLS as stated in the guidelines from the Norwegian Resuscitation Council and the European Resuscitation Guidelines. Recently, REBOA has been proposed as an adjunct treatment in management of non-traumatic cardiac arrest patients, because thoracic aortic occlusion provides a redistribution of the cardiac output to organs proximal to the occlusion. Preclinical studies demonstrate that REBOA during CPR provide both increased coronary artery blood flow and perfusion pressure and increased rates of return of spontaneous circulation (ROSC). This is the first prospective trial in the world to assess the efficacy of REBOA in non-traumatic cardiac arrest. The intervention is shown feasible in the pre-hospital setting. If this trial provides a signal of benefit in patients, this study could initiate further clinical research which could change current resuscitation practice world-wide.
This is a prospective, randomised, parallel group, multi-centre, phase II clinical trial. Patients are randomised in a 1:1 ratio to be included to the control group or the intervention group. The control group receives ACLS according to national guidelines, while the intervention group receives ACLS according to national guidelines and the REBOA procedure as an adjunct treatment. The REBOA procedure is performed by a team consisting of a physician (anesteshiologist) and a paramedic, working at a helicopter emergency medical service (HEMS) base. All operators will be properly educated and tested before they can include patients. If the patients in the intervention group achieves ROSC, the balloon will be deflated and post-ROSC treatment will be continued as per routine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
200
Resuscitative endovascular balloon occlusion of the aorta (REBOA)
Treatment as described in the guidelines from the European Resuscitation Council, the Norwegian Resuscitation Council, and other local national guidelines
Aarhus Base
Aarhus, Denmark
Billund HEMS-base
Billund, Denmark
Ringsted HEMS-base
Ringsted, Denmark
Skive HEMS
Skive, Denmark
Maggiore Hospital
Bologna, Italy
Haukeland University Hospital
Bergen, Norway
Drammen Hospital
Drammen, Norway
Lørenskog HEMS Unit
Oslo, Norway
Rapid response car - 119 Oslo
Oslo, Norway
Stavanger University Hospital
Stavanger, Norway
...and 1 more locations
Proportion of patients that achieve return of spontaneous circulation (ROSC) with a duration of at least 20 minutes.
Sustained ROSC means return of spontaneous circulation with a duration of at least 20 minutes.
Time frame: 60 minutes
The proportion of patients surviving to 30 days with good neurologic status, defined as a modified Rankin scale (mRS) score 0-3.
The mRs are dichotomised into good (score 0-3) and poor (score 4-6) neurological state.
Time frame: 30 days
Difference in end-tidal CO2 (EtCO2) measurements between control group and intervention group after aortic occlusion.
In the control group, EtCO2 is measured after airway management is completed. In the intervention group, EtCO2 is measured after airway management is completed, before balloon inflation and 30, 60 and 90 seconds after balloon inflation.
Time frame: 15 minutes
Change in blood pressures after aortic occlusion
In the intervention group, intra-aortic blood pressure measurements from the REBOA catheter are recorded. This applies only to the catheters with CE/FDA approval for invasive blood pressure measurements and will therefore be assessed in a sub-group of the participants. Continuous registration of invasive blood pressure will start before aortic occlusion.
Time frame: 15 minutes
Difference in left ventricular ejection fraction (LVEF) measured by echocardiography
Echocardiography after admission, after a few days-up to one week and at discharge will be assessed - both from the control and intervention group.
Time frame: 1-2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.